Here are 1-3 brief analogies for GeneDx:

• Quest Diagnostics for complex genetic diagnoses.

• LabCorp, but exclusively for uncovering rare genetic disease causes.

• Like 23andMe, but focused on clinical diagnosis and treatment guidance for rare diseases.

• Genomic Testing for Rare Diseases: Diagnostic genetic testing services focused on identifying the genetic causes of rare and undiagnosed conditions.
• Hereditary Cancer Testing: Genetic testing to assess an individual's risk of developing hereditary forms of cancer and guide early detection or prevention strategies.
• Pharmacogenomic Testing (PGx): Genetic tests that analyze how a person's genes affect their response to certain medications, aiding in personalized drug selection and dosing.

GeneDx (symbol: WGS) primarily sells its genomic testing services to other companies and institutions, specifically healthcare providers.

According to its latest annual report (10-K filing for the fiscal year ended December 31, 2023), GeneDx's customer base is highly fragmented, with no single customer representing more than 10% of its revenue for the years ended December 31, 2023, 2022, and 2021. Therefore, there are no specific "major customer companies" that can be named individually as significant revenue contributors.

However, the company serves a broad range of institutional customers who order genetic tests for their patients. These include:

• Hospitals and academic medical centers
• Specialized clinics (such as genetics, neurology, or pediatric clinics)
• Individual physicians and private practices

• Illumina, Inc. (ILMN)
• Thermo Fisher Scientific Inc. (TMO)
• Integrated DNA Technologies, Inc.

Katherine Stueland, Chief Executive Officer

Katherine Stueland was appointed President and CEO of GeneDx (Nasdaq: WGS) in June 2021. Her career has focused on transforming healthcare through patient-centric businesses, including supporting FDA approvals for rare disease therapeutics, the first protease inhibitor for HIV/AIDS, and the first cancer immunotherapy. Before joining GeneDx, she served as Chief Commercial Officer at Invitae Corporation, where she was instrumental in establishing the corporate brand as the company transitioned from a private entity to a public one with a market capitalization exceeding $6 billion. At Invitae, she led a sales and business development organization of over 200 people and spearheaded the company's expansion into more than 100 international markets. She also held roles at Dendreon Corporation and TAP Pharmaceuticals.

Kevin Feeley, Chief Financial Officer

Kevin Feeley serves as Chief Financial Officer at GeneDx, leading financial strategy, management, and planning. He brings over 20 years of finance and accounting leadership experience across the healthcare, pharmaceutical, and diagnostics sectors. Prior to GeneDx, Mr. Feeley was CFO of OPKO Health's diagnostics division, which included BioReference Laboratories, Inc. and GeneDx, for six years. His previous roles include U.S. Controller at Reckitt Benckiser and leading SEC reporting at Bausch Health Companies. He also spent twelve years in the audit practice of KPMG LLP, working with large multinational pharmaceutical companies. While his legal practice focused on the taxation of complex transactions, including private equity investments and advising sponsors of private equity funds, his executive management experience at GeneDx and its prior iterations involved oversight during acquisitions by public entities rather than a direct pattern of managing companies backed by private equity firms as an executive.

Bryan Dechairo, Chief Operating Officer

Bryan Dechairo was appointed Chief Operating Officer of GeneDx in January 2025. In this role, he oversees Product & Technology, Operations, Medical Affairs, Innovation, and Program Management teams. With over 30 years of experience in exploratory and commercial diagnostic businesses, Mr. Dechairo most recently served as President and CEO of Sherlock Biosciences, where he transitioned the company from a research-stage startup to a commercial operation. He has held executive leadership positions at other prominent diagnostic and pharmaceutical companies, including Pfizer, Myriad Genetics, Assurex, and Medco Health.

Heidi Chen, Chief Legal Officer

Heidi Chen is the Chief Legal Officer at GeneDx. As Chief Legal Officer, she is responsible for the company's legal affairs.

Melanie Duquette, Chief Growth Officer

Melanie Duquette was appointed Chief Growth Officer at GeneDx in September 2023. She is responsible for the company's overall growth strategy, leading sales, market access, clinician marketing, and client services functions. Ms. Duquette brings nearly 20 years of genomic industry experience, having previously spent a decade at Invitae, where she drove commercial growth strategies and expanded genetic testing utilization. Her roles at Invitae included Head of US Sales and leading the company's entry into over 100 international markets.

GeneDx (symbol: WGS) primarily focuses on genetic testing services, with a strong emphasis on whole exome and genome sequencing for pediatric and rare disease diagnostics. The company also provides data and information services and is developing an AI-based platform for analysis, interpretation, and clinical reporting for rare disease, hereditary risk, and cancer testing.

The addressable markets for GeneDx's main products and services are primarily within the U.S. and are sized as follows:

• The immediate market for rare diseases and pediatrics was estimated at $3 billion as of Q2 2024.
• The total addressable market for GeneDx's offerings was estimated at $45 billion by Q4 2024. A conservative estimate places the total addressable market at approximately $30 billion.
• The market for adults, as GeneDx expands into cardiology and neurology to replace multi-gene panel and individual gene tests, is estimated at $16 billion.
• The newborn screening market is estimated at $10 billion.

GeneDx's ultraRapid Whole Genome Sequencing (WGS), launched in early 2025, further expands their addressable market into urgent-care diagnostics, particularly in neonatal and pediatric intensive care units (NICU/PICU). The company holds an estimated 80% market share in the U.S. Exome market.

• Accelerated Growth in Exome and Genome Testing Volume: GeneDx anticipates sustained and accelerating growth in the volume of its exome and genome tests. The company has consistently reported impressive year-over-year increases in exome and genome test revenue and volume, projecting at least 30% volume growth for the full year 2025. This growth is a core component of their revenue strategy.
• Expansion into New Markets and Indications: GeneDx is actively expanding its commercial reach by introducing new indications for its exome and genome testing, such as for cerebral palsy and inborn errors of immunity. The company is also strategically targeting broader market penetration, including expanding into the general pediatrician and neonatal intensive care unit (NICU) settings. This expansion is supported by plans to nearly double its sales force.
• Launch and Growth of New Products and Services: The introduction of new offerings, such as the ultraRapid Whole Genome Sequencing product, designed to provide accelerated genomic insights for neonatal and pediatric patients, is expected to contribute to incremental volume growth. Furthermore, the acquisition of Fabric Genomics aims to accelerate GeneDx's entry into decentralized genomic medicine and establish a recurring software revenue stream.
• Improved Reimbursement and Payer Coverage: Efforts to enhance reimbursement rates and reduce claim denial rates for exome and genome tests are a key driver. GeneDx is also benefiting from the expansion of Medicaid coverage for exome and genome sequencing in additional states and is actively working to shape equitable access and reimbursement policies.
• Leveraging the Infinity Rare Disease Dataset and Data Interpretation Platform: GeneDx's proprietary Infinity dataset, which is the largest rare disease dataset, and its advanced data interpretation platform are crucial for differentiating its offerings. By continuously expanding and utilizing this dataset, the company can strengthen relationships with clinicians and reinforce reimbursement rates, thereby indirectly driving revenue through enhanced test adoption and perceived value.

No information available on share repurchase programs or amounts over the last 3-5 years.

• In January 2023, GeneDx completed an underwritten public offering and a concurrent registered direct offering, issuing 406,419,805 shares of Class A common stock at $0.35 per share, with expected gross proceeds of approximately $150 million.
• In May 2022, in connection with the acquisition of GeneDx, Sema4 (now GeneDx) completed a $200 million private placement by issuing Class A common stock at $4.00 per share to institutional investors, including Pfizer.

• In May 2022, Sema4 (now GeneDx) secured a $200 million private placement from leading growth and life sciences investors, including Pfizer.
• On September 30, 2024, Goldman Sachs Group Inc. acquired 1,337,105 shares of GeneDx Holdings Corp. at $42.44 per share, increasing its stake to approximately 5% of the company.
• During 2025, various institutional investors and hedge funds, including Jones Financial Companies Lllp, US Bancorp DE, and AlphaQuest LLC, significantly increased their positions in GeneDx.

• On April 29, 2022, Sema4 (the company that became GeneDx) completed the acquisition of GeneDx, Inc. from OPKO Health, Inc. for approximately $623 million. This included $150 million in upfront cash, 80 million shares of Sema4 common stock, and up to $150 million in revenue-based milestones.
• GeneDx announced plans to acquire Fabric Genomics, an AI-powered genomic interpretation pioneer, with the acquisition expected to close in the second quarter of 2025.

• Capital expenditures were reported as -$5 million for the fiscal year ending December 30, 2024.
• The company's capital expenditures are primarily focused on expanding laboratory operations, enhancing offerings, and supporting sales and marketing efforts to achieve profitability by 2025.
• Investments are being made to broaden the testing population in outpatient pediatric settings, NICU, adult conditions, and newborn screening, as well as to launch major enhancements to whole genome sequencing (WGS) products.